Is Abbott India (ABBOTINDIA) overvalued or fairly valued?

MarketChacha shows Abbott India's valuation in context — a forward P/E of about 29.9, a price-to-book of about 12.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Abbott India's revenue?

Abbott India reported revenue of ₹6,929 Cr for FY2026, with net profit of ₹1,552 Cr, per official filings.

What is the share price of Abbott India (ABBOTINDIA)?

Abbott India last traded at ₹26,730.00 (-1.2% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Abbott India

ABBOTINDIA · NSE · Pharma · India

Snapshot

TickerABBOTINDIA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees3,679

HeadquartersMumbai, India

Websitewww.abbott.co.in

Filings tracked0

About Abbott India

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

Who owns it

Promoters75.5%
Institutions7.6%
Public & other16.9%

46 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend17.8% → 22.4%

Margin has expanded by about 4.6 points — the business is getting more profitable.

Growth qualityrev 7% · PAT 13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹8,241 Cr · EPS 904.77

Est. earnings growth +12.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹6,929 Cr

Net margin

22.4%

Revenue CAGR (3y)

+9.0%

Profit CAGR (3y)

+17.8%

Net profit (FY2026)

₹1,552 Cr

Ask MarketChacha about ABBOTINDIA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹6,929 Cr	₹1,552 Cr	22.4%
FY2025	₹6,409 Cr	₹1,414 Cr	22.1%
FY2024	₹5,849 Cr	₹1,201 Cr	20.5%
FY2023	₹5,349 Cr	₹949 Cr	17.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
Q1 FY27	₹1,814 Cr	₹429 Cr	201.66	23.6%
Q4 FY26	₹1,710 Cr	₹395 Cr	—	23.1%
Q3 FY26	₹1,724 Cr	₹376 Cr	—	21.8%
Q2 FY26	₹1,757 Cr	₹415 Cr	—	23.6%
Q1 FY26	₹1,738 Cr	₹366 Cr	—	21.0%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.